MDT-AP-1161
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 81
- os_event
- false
- age_years
- 7.8
- sex
- F
- new_clusters
- C3
- umap1_2d
- 5.766149195
- umap2_2d
- 2.003270636
- umap1_3d
- 1.841377045
- umap2_3d
- -2.861183727
- umap3_3d
- -1.495604255
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.210
- SPERMATOGENESIS+0.060
- BILE_ACID_METABOLISM+0.030
- DNA_REPAIR+0.020
- APICAL_SURFACE-0.010
- PEROXISOME-0.020
- APICAL_JUNCTION-0.030
- PANCREAS_BETA_CELLS-0.030
- WNT_BETA_CATENIN_SIGNALING-0.040
- MYOGENESIS-0.090
Top 10 suppressed
- MYC_TARGETS_V1-0.560
- E2F_TARGETS-0.520
- G2M_CHECKPOINT-0.520
- HEDGEHOG_SIGNALING-0.440
- MTORC1_SIGNALING-0.440
- NOTCH_SIGNALING-0.440
- TNFA_SIGNALING_VIA_NFKB-0.400
- INFLAMMATORY_RESPONSE-0.380
- TGF_BETA_SIGNALING-0.380
- CHOLESTEROL_HOMEOSTASIS-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | aMVAC.P_005_TURBT_S223 | — | — | 0.919 |
| 2 | MDT-AP-1160 | Med | Medulloblastoma | 0.912 |
| 3 | SRR1797231 | — | cohortSC | 0.912 |
| 4 | ERR2278876 | — | — | 0.907 |
| 5 | SJEPD007_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.906 |
| 6 | SJEPD001530_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.906 |
| 7 | MDT-AP-2034 | Med | Medulloblastoma | 0.905 |
| 8 | 8ad884fa-e426-4bc0-960d-08db42d341da | — | — | 0.901 |
| 9 | TCGA-E7-A3Y1-01A-11R-A22U-07 | — | — | 0.898 |
| 10 | SRR1516050 | — | — | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 4 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |